US2018187161A1PendingUtilityA1
Differentiating induced pluripotent stem cells into glucose-responsive, insulin-secreting progeny
Assignee: MAYO FOUND MEDICAL EDUCATION & RESPriority: Jul 22, 2011Filed: Feb 22, 2018Published: Jul 5, 2018
Est. expiryJul 22, 2031(~5 yrs left)· nominal 20-yr term from priority
C12N 2500/90C12N 2500/99C12N 2501/16C12N 2501/41C12N 5/0696C12N 2501/608C12N 2501/606C12N 2506/45C12N 2501/602C12N 2501/119C12N 2501/60C12N 2501/605C12N 2501/385C12N 2501/335C12N 2500/98C12N 2500/46C12N 2501/415C12N 5/0677C12N 2501/727C12N 2501/604C12N 2501/603
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A method for obtaining a population of glucose-responsive, insulin-secreting cells from a human, wherein said method comprises:
(a) obtaining somatic cells from a human, (b) exposing said somatic cells to one or more polypeptides or nucleic acids encoding said one or more polypeptides to form induced pluripotent stem cells, wherein said one or more polypeptides are selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide, and (c) culturing said induced pluripotent stem cells with medium comprising indolactam V and glucagon like peptide-1 to obtain said population of glucose-responsive, insulin-secreting cells.
3 . The method of claim 2 , wherein said medium lacks serum.
4 . The method of claim 2 , wherein said culturing is performed in the absence of feeder cells.
5 . The method of claim 2 , wherein said culturing is performed in the absence of non-human feeder cells.
6 . The method of claim 2 , wherein said somatic cells are selected from the group consisting of skin, lung, heart, stomach, brain, liver, blood, kidney, and muscle cells.
7 . The method of claim 2 , wherein said induced pluripotent stem cells comprise exogenous nucleic acid encoding a human Oct4 polypeptide, a human Sox2 polypeptide, a human Klf4 polypeptide, and a human c-Myc polypeptide.
8 . The method of claim 2 , wherein said medium comprises between about 200 nM and about 400 nM of indolactam V.
9 . The method of claim 2 , wherein said medium comprises between about 25 nM and about 75 nM of glucagon like peptide-1.
10 . The method of claim 2 , wherein said culturing is performed for about 10 to 25 days.Join the waitlist — get patent alerts
Track US2018187161A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.